Evidence map›Paper›PMID 41290338›Full record

ReviewNeurosciences (Riyadh, Saudi Arabia)2025

Metabotropic glutamate receptors: Allosteric structural modulation and new treatments for anxiety disorders.

Madaniah O Zakari

Abstract readReview
In one paragraph

Review in Neurosciences (Riyadh, Saudi Arabia), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Madaniah O ZakariFrom the Department of Basic Medical Sciences, College of Medicine, Taibah University, Madinah, Kingdom of Saudi Arabia.ORCID https://orcid.org/0009-0008-2232-1987

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anxiety disorders are psychiatric ailments that affect people throughout the world. Several studies have revealed that the development of anxiety is affected by changes in glutamatergic neurotransmission. Metabotropic glutamate receptors (mGluRs) can be allosterically modified, offering a new strategy for developing specific therapeutic agents that affect the cell membrane. Allosteric modulators have many advantages over other therapeutic options. In the field of stress treatment modulation, they can maintain the properties of natural glutamatergic neurotransmission. This review describes the design of allosteric modulators and the advantages of this class of compounds over current stress drugs.

Indexed as

Anti-Anxiety AgentsAnxiety DisordersReceptors, Metabotropic GlutamateAllosteric RegulationAnimalsHumansAnti-Anxiety AgentsReceptors, Metabotropic Glutamate

Identifiers

PMID41290338
PMCPMC12676932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.